Pharmaceutical

Zealand Pharma steadfastly upholds amylin-based obesity drug strategy

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and development timeline.

Feb 21, 2025 - 06:00
Zealand Pharma steadfastly upholds amylin-based obesity drug strategy
Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and development timeline.
Read the original article

Tags:

Previous Article

FibroGen sells China unit to AstraZeneca for $160m

Next Article

X4 and taiba to distribute WHIM syndrome therapy in Middle East

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Adcendo amps up ADC development with €82 million series A extension

Adcendo amps up ADC development with €82 million series...

Apr 4, 2023

Does the hype around generative AI reflect its technology progress?

Does the hype around generative AI reflect its technolo...

Jul 5, 2023

Revenue growth for 13 of top 20 biopharmas with obesity drug successes in 2023

Revenue growth for 13 of top 20 biopharmas with obesity...

Aug 1, 2024